Clinical Trial Update: The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1b/IIa open-label study evaluating safety, tolerability, and preliminary efficacy of combining HCB101 with Cetuximab or Bevacizumab plus FOLFOX/FOLFIRI in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Bevacizumab (bevacizumab)
• Cetuximab (cetuximab)
• HCB101 (HCB101)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Chang Gung Memorial Hospital | Conditions: CRC | Phase 1, Phase 2 | Status: RECRUITING